No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Software group Cambridge Cognition said on Thursday that it has secured a £1.0m contract to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial.
Cambridge Cognition said the initial contract, which was with "a major pharmaceutical company", will start in 2025 and run through to 2031.
The AIM-listed firm noted that it has previously provided services to this customer, with the new contract representing repeat business with the "global company".
Cambridge Cognition added that it was selected to support the study due to its "scientifically validated, proprietary cognitive assessments" and its "proven ability to deliver digital cognitive testing solutions on a global scale".
Supported by an experienced clinical project management team, Cambridge Cognition will deploy its CANTAB asset will be deployed in 16 countries and 23 languages across 245 trial sites.
As of 1150 BST, Cambridge Cognition shares were up 0.20% at 33.06p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
